SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Mary McLeod Bethune

PatientMary McLeod Bethune
Date of birth1953-07-10
IdentifiersMRN HR-ML043-SYN; SSN (made up) 000-43-2195
Document date2026-05-04
AuthorViola Harrington-Mbeki, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-week asthma review. [S]

History of Present Illness

Mrs. Bethune returns six weeks after starting budesonide-formoterol. Her nights are better, waking once a week, but she is still breathless on stairs some days and has used the inhaler as a reliever three or four times a week. The dose counter shows she has taken about 70 percent of her maintenance doses: she sometimes forgets the evening dose when she is working late. She saw the ear, nose and throat specialist two weeks ago; nasal endoscopy showed chronic rhinosinusitis without polyps, and her nose is clearer on the steroid spray. Heartburn has gone on omeprazole. Home blood pressure averages 132/78. She has had no ankle swelling on amlodipine and no muscle aches on atorvastatin. She has had no thoughts of self-harm. [S]

ElementDetail
ControlAsthma Control Test 18; night waking once a week; reliever three or four times a week
AdherenceAbout 70 percent of maintenance doses by the dose counter
Ear, nose and throatChronic rhinosinusitis without nasal polyps on endoscopy
Home blood pressureAverage 132/78

Review of Systems

SystemResultFinding
RespiratoryPositiveNight waking once a week; breathless on stairs some days
Ears, nose, mouth, and throatPositiveNose clearer; smell a little better; no hoarseness or thrush
GastrointestinalNegativeNo heartburn on omeprazole
CardiovascularNegativeNo ankle swelling, chest pain or palpitations
MusculoskeletalNegativeNo muscle aches

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Albuterol 90 mcg/actuation inhaler, two puffs as needed, from an urgent care visit four months ago (used alone, without an inhaled steroid)Two puffs every 4 hours as needed; she uses it most daysRespiratory tract route2025-11-03 to 2026-03-23completedS
Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a dayOne inhalation twice daily plus one as neededRespiratory tract route2026-03-23 to 2026-06-15completedS
Fluticasone propionate 50 mcg/actuation nasal spray, two sprays in each nostril once daily, aimed away from the septumTwo sprays each nostril dailyNasal route2026-03-23activeS
Sodium chloride 0.65% nasal spray, two sprays in each nostril up to four times daily before the steroid sprayTwo sprays each nostril up to four times dailyNasal route2026-03-23activeS
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-23activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-23activeS
Omeprazole 20 mg delayed-release capsule, one capsule daily 30 minutes before breakfast for eight weeksOne capsule daily before breakfastOral route2026-03-23 to 2026-05-18completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-05-04Body height163cmS
2026-05-04Body weight87kgS
2026-05-04Body mass index (BMI) [Ratio]32.7kg/m2S
2026-05-04Systolic blood pressure134mm[Hg]S
2026-05-04Diastolic blood pressure80mm[Hg]S
2026-05-04Heart rate76/minS
2026-05-04Respiratory rate16/minS
2026-05-04Body temperature36.6CelS
2026-05-04Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-05-04Total score [ACT]18{score}S
2026-05-04Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
2026-05-04Creatinine [Mass/volume] in Serum or Plasma0.94mg/dL0.59-1.04 mg/dLNormalS
2026-05-04Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M64mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-05-04Cholesterol [Mass/volume] in Serum or Plasma170mg/dL<=199 mg/dLNormalS
2026-05-04Cholesterol in HDL [Mass/volume] in Serum or Plasma57mg/dL50 mg/dL or more for womenNormalS
2026-05-04Triglyceride [Mass/volume] in Serum or Plasma126mg/dL<=149 mg/dLNormalS
2026-05-04Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation88mg/dL<=99 mg/dLNormalS

Physical Exam

Vital signs recorded on 2026-05-04; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 87.0 kg; blood pressure 134/80, pulse 76; oxygen saturation 97 percent
MouthNo thrush
RespiratoryA few expiratory wheezes on forced expiration
ExtremitiesNo ankle edema

Problems

ProblemClinical statusVerificationCodeProvenance
Wheeze, cough and breathlessness for four months: waking with cough and tight chest two or three nights a week, breathless on one flight of stairs, relieved by albuterol, worse with colds, dust and strong scents; known asthma for many years but never confirmed by lung function testing and never treated with an inhaled steroid. Asthma, COPD and heart failure to be distinguished: spirometry with bronchodilator response, FeNO and an echocardiogram bookedresolvedconfirmed R06.2S — Synthetic presenting problem anchored to her documented chronic asthma. Superseded by the diagnosis at the second visit.
Blocked nose, thick postnasal drip and a reduced sense of smell for years, worse in the last year; no nosebleeds; never seen by an ear, nose and throat specialistresolvedconfirmed R09.81S — Synthetic upper-airway symptoms; superseded by the diagnosis of chronic rhinosinusitis after nasal endoscopy.
Gastro-esophageal reflux: heartburn and an acid taste two or three evenings a week, worse after late meals and lying down; no trouble swallowing, vomiting, black stools or weight lossactiveconfirmed K21.9S — Synthetic comorbidity of asthma; not a claim about her real health.
Obesity, class 1 (BMI 33.1); she wants to walk more and to keep up with her work, and agreed to talk about itactiveconfirmed E66.811S — Synthetic comorbidity recorded in her words and with her agreement; not a claim about her real weight.
Asthma, confirmed: variable airflow obstruction (FEV1 64 percent predicted, rising 270 mL or 21 percent after bronchodilator, with a normal post-bronchodilator FEV1/FVC of 0.72 and normal DLCO); type 2 inflammation (FeNO 46 ppb, blood eosinophils 0.42 x10^3/uL, total IgE 210, house dust mite sensitization); not COPD and not heart failure. Uncontrolled at diagnosis on albuterol aloneactiveconfirmed J45.40S — Synthetic modern confirmation linked to her documented chronic asthma.
Hypertensive heart disease without heart failure: clinic blood pressure 152/88 and 146/86, home average 144/84; mild concentric left ventricular hypertrophy with grade 1 diastolic dysfunction and a normal ejection fraction (62 percent); BNP 48 pg/mLactiveconfirmed I11.9S — Synthetic finding of the modern work-up; not a claim about her real heart.
Hyperlipidemia: LDL cholesterol 144 mg/dL; 10-year ASCVD risk above 20 percent with hypertensionactiveconfirmed E78.5S — Synthetic cardiovascular risk factor.
Chronic rhinosinusitis without nasal polyps: years of congestion, postnasal drip and reduced smell, with mucosal swelling and mucus in both middle meatuses and no polyps on nasal endoscopyactiveconfirmed J32.9S — Synthetic upper-airway comorbidity of asthma; not a claim about her real health.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyAsthma Control Test, symptoms, night waking and reliever useEvery visitCompleted todayAsthma Control Test 18; night waking once a week; reliever three or four times a week
ExaminationInhaler technique with her own inhaler, and adherenceEvery visit; before any step-upCompleted todayThree errors (not shaking, fast breath in, no breath-hold) corrected with a spacer; adherence about 70 percent by dose counter
Self-managementExacerbation history (oral corticosteroid courses, emergency visits, admissions)Every visitCompleted todayNone since the last visit
Self-managementStep-up or step-down assessment (GINA track 1)Every visitCompleted todayNo step-up until technique and adherence are corrected
Self-managementWritten asthma action planEvery visit and after every exacerbationCompleted todayReviewed; peak flow diary to set her personal best
Self-managementTriggers, exposures and smoking or vapingEvery visitCompleted todayDust mite covers in place; avoids perfume at meetings where she can
ImagingSpirometry after stabilizationThree to six months after starting treatmentDuePlanned for the next visit
ExaminationComorbiditiesAt diagnosis and yearlyCompleted todayChronic rhinosinusitis confirmed; reflux settled
ExaminationBlood pressure in clinic and at homeEvery visit; home readings at diagnosis and after changesCompleted todayClinic 134/80; home average 132/78
LaboratoryPotassium and kidney function after starting treatmentAfter starting or changing antihypertensive treatmentCompleted todayPotassium 4.2, creatinine 0.94, eGFR 64
LaboratoryLipid panel after starting a statinFour to twelve weeks after starting, then yearlyCompleted todayTotal cholesterol 170, HDL 57, triglycerides 126, LDL 88

Goal progress:

Guideline basis: CMID: Clinical Monitoring Intelligence Database, asthma and hypertension monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025)

Follow-up: Next planned review in about three months, sooner for any change. Call the clinic in the yellow zone of her action plan. Next scheduled visit 2026-07-27: review six weeks after an exacerbation: control, repeat spirometry and FeNO, biologic assessment, blood pressure and the post-exacerbation plan. [S]